Competitor Exit A Boom For Respiratory Device-Focused Inogen, Earns Analyst Upgrade
Portfolio Pulse from Vandana Singh
Inogen Inc (NASDAQ:INGN) has been upgraded by William Blair from Market Perform to Outperform following Koninklijke Philips NV's (NYSE:PHG) announcement to halt sales of new CPAP, BiPAP, and other respiratory devices in the U.S. until compliance with a consent decree. Philips Respironics will continue operations internationally under specific conditions. The exit of Respironics, a significant market player, presents an opportunity for Inogen to capture a larger market share, potentially up to 50% compared to Respironics' 15%-25%. Despite recent challenges and management changes at Inogen, the analyst views the current valuation and market opportunity as favorable for the company.
February 15, 2024 | 7:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Koninklijke Philips NV announced it would halt sales of new CPAP, BiPAP, and other respiratory devices in the U.S. until compliance with a consent decree, potentially affecting its market share and positioning in the respiratory device market.
Philips' decision to halt sales in the U.S. market is a significant move that could negatively impact its market share and financial performance in the short term. This decision opens up opportunities for competitors like Inogen to capture a larger portion of the market.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Inogen Inc has been upgraded by William Blair from Market Perform to Outperform, indicating a positive outlook for the company's stock. This upgrade follows Philips' decision to halt sales of respiratory devices in the U.S., presenting a significant market opportunity for Inogen.
The upgrade by William Blair is a direct response to Philips' market exit in the U.S., which opens up a significant opportunity for Inogen to increase its market share. The analyst's positive outlook is based on Inogen's potential to capture new shares and its favorable valuation.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100